Discounted Cash Flow
Ultragenyx Pharmaceutical Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $133.0k | $-245.9m | $-171.2m | -184867.7% | — |
| 2017 | $2.6m (1863.9%) | $-302.1m (-22.9%) | $-256.6m (-49.9%) | -11567.3% (93.7%) | — |
| 2018 | $51.5m (1871.5%) | $-197.6m (34.6%) | $-294.6m (-14.8%) | -383.7% (96.7%) | — |
| 2019 | $103.7m (101.4%) | $-402.7m (-103.8%) | $-370.2m (-25.6%) | -388.3% (-1.2%) | — |
| 2020 | $271.0m (161.3%) | $-186.6m (53.7%) | $-176.1m (52.4%) | -68.8% (82.3%) | $-3.07 |
| 2021 | $351.4m (29.7%) | $-454.0m (-143.4%) | $-411.8m (-133.8%) | -129.2% (-87.7%) | $-6.70 (-118.2%) |
| 2022 | $363.3m (3.4%) | $-707.4m (-55.8%) | $-496.6m (-20.6%) | -194.7% (-50.7%) | $-10.12 (-51.0%) |
| 2023 | $434.2m (19.5%) | $-606.6m (14.2%) | $-519.1m (-4.5%) | -139.7% (28.3%) | $-8.25 (18.5%) |
| 2024 | $560.2m (29.0%) | $-569.2m (6.2%) | $-421.7m (18.8%) | -101.6% (27.3%) | $-6.29 (23.8%) |
| 2025 | $673.0m (20.1%) | $-575.0m (-1.0%) | $-472.0m (-11.9%) | -85.4% (15.9%) | $-5.83 (7.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.